Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faricimab
- Development stage
- Approved
- Lead developer
- Roche
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Faricimab is a humanized bispecific monoclonal antibody that simultaneously targets and inhibits both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2). By blocking these two pathways, it suppresses abnormal blood vessel growth, reduces vascular permeability, and stabilizes retinal blood vessels. Faricimab is the first bispecific antibody approved for ophthalmologic use and is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It is administered by intravitreal injection. The drug was developed by Roche/Genentech[2][3][5][6].
- Brand names
- Vabysmo
- Other names
- faricimab-svoa
02
Targets
ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on faricimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faricimab.